EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price

Julia Caroline Michaeli, Thomas Michaeli, Dario Trapani, Sebastian Albers, Dominik Dannehl, Rachel Würstlein, Daniel Tobias Michaeli

Breast Cancer · 2024

DOI: 10.1007/s12282-024-01634-x ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Breast Cancer, 2024. Verfasst von Julia Caroline Michaeli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, LMU University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Approval, United States Food and Drug Administration, Quality of Life. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Heidelberg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study analyzes the development, benefits, trial evidence, and price of new breast cancer drugs with US Food and Drug Administration (FDA) approval.

Methods

We identified 26 drugs with 42 FDA-approved indications for early and metastatic breast cancer (2000–2023). Data were collected from FDA labels, clinicaltrials.gov, and Medicare and Medicaid. Overall survival (OS) and progression-free survival (PFS) hazard ratios (HRs) and tumor response’s relative risk (RR) alongside objective response rate (ORR) were meta-analyzed.

Results

The median development time for breast cancer drugs was 7.8 years (95% CI 6.2–10.8). 26% of treatments were considered innovative (“first-in-indication”) with 88% acting via a targeted mechanism. 64% were small molecules, 19% antibodies, and 18% antibody-drug conjugates. 38% were approved for HR + and 31% for HER2 + breast cancer. 6 indications were for early and 36 for metastatic breast cancer. Indications utilized FDA’s special programs: orphan (2%), fast track (24%), accelerated approval (19%), priority review (74%), breakthrough therapy (44%). Approval was predominantly supported by phase 3 trials (88%) of randomized controlled design (66%), enrolling a median of 585 patients (IQR 417–752) at 181 centers (IQR 142–223) across 19 countries (IQR 17–20). New drugs’ HR were 0.78 for OS (95% CI 0.74–0.82) and 0.59 for PFS (95% CI 0.54–0.64) with a RR for tumor response of 1.61 (95% CI 1.46–1.76). Median improvements of OS were 2.8 months (IQR 1.8–5.8) and PFS were 4.4 months (IQR 2.2–7.1). In single-arm trials, the average ORR was 31% (95% CI 10–53). In meta-regressions, the correlation between OS/PFS was 0.34 ( p = 0.031) and OS/response was 0.01 ( p = 0.435). 60% of treatments had a ‘ high-value ’ ESMO-MCBS score with 14% demonstrating improvements in quality of life. The median price was $16,013 per month (95% CI 13,097–17,617). There was no association between prices and patient benefit. The median value per life year gained was $62,419 (IQR 25,840–86,062).

Conclusions

Over the past two decades, the development of innovative and effective drugs transformed the treatment landscape for breast cancer patients. Yet, investigators and regulators must safeguard that highly-priced new drugs demonstrate improvements in patient-centered clinical endpoints: overall survival and quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsDrug ApprovalUnited States Food and Drug AdministrationQuality of LifeAntineoplastic AgentsHumansFemaleUnited StatesClinical Trials as TopicProgression-Free Survival

Stichwörter der Autor:innen

AntibodyAntibody-drug conjugatesBRCABiomarkerBreast cancerCancer drugsClinical trialsESMO-MCBSEarly breast cancerFDA approvalHER2Hormone receptorInnovationMetastatic breast cancerObjective response rate

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Obstetrics and Gynaecology, LMU University Hospital, LMU Munich, Munich, Germany.
  • Department of Personalized Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany.
  • Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • European Institute of Oncology, IRCCS, Milan, Italy.
  • Department of Oncology and Hematology, University of Milan, Milan, Italy.

Förderung

  • Universitätsklinikum Heidelberg

Zitieren

APA

Michaeli, J. C., Michaeli, T., Trapani, D., Albers, S., Dannehl, D., Würstlein, R., & Michaeli, D. T. (2024). Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price. Breast Cancer. https://doi.org/10.1007/s12282-024-01634-x

Vancouver

Michaeli JC, Michaeli T, Trapani D, Albers S, Dannehl D, Würstlein R, et al. Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price. Breast Cancer. 2024. doi:10.1007/s12282-024-01634-x

BibTeX
@article{Michaeli2024,
  author = {Michaeli, Julia Caroline and Michaeli, Thomas and Trapani, Dario and Albers, Sebastian and Dannehl, Dominik and Würstlein, Rachel and Michaeli, Daniel Tobias},
  title = {Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price},
  journal = {Breast Cancer},
  year = {2024},
  doi = {10.1007/s12282-024-01634-x}
}
Kostenlos starten →